Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected subjects treated with HAART

Next Previous
Trial Profile

A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected subjects treated with HAART

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Abbott Healthcare Products

Most Recent Events

  • 21 Apr 2010 Actual number of patients (51) added as reported by ClinicalTrials.gov record.
  • 21 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 15 Feb 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top